Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Platinum-doublet rechallenge after prior platinum and immunotherapy in advanced non-small cell lung cancer
jRCTs061240065Phase 2Recruiting
- Start
- Dec 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of carboplatin, paclitaxel, pemetrexed and gemcitabine in non-small cell lung cancer (NSCLC) (4 arms). Primary endpoint: Progression-free survival. Started Dec 2024; status: recruiting.
02
Drugs
carboplatinpaclitaxelpemetrexedgemcitabine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs061240065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061240065.